InnoCare Pharma Limited (HKG:9969)

Market Cap	18.88B
Revenue (ttm)	995.67M
Net Income (ttm)	-415.92M
Shares Out	1.76B
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,024,000
Average Volume	14,144,067
Open	9.26
Previous Close	9.21
Day's Range	8.97 - 9.70
52-Week Range	4.03 - 10.02
Beta	1.03
RSI	79.35
Earnings Date	Mar 28, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,089
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9969

Financial Performance

In 2023, InnoCare Pharma's revenue was 738.54 million, an increase of 18.09% compared to the previous year's 625.40 million. Losses were -631.26 million, -28.80% less than in 2022.

Financial numbers in CNY